News | November 30, 2025
MHRA clears inavolisib, offering new option for returning breast cancer
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
This distinction is testament to LHWRF's dedication to excellence, transparency, and impact in the realm of social responsibility
Most recently, Yuvraj was the Director of Operations, Business Development & Process Excellence at Zeon Lifesciences Ltd
GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
Owlet’s push comes as parents demand smarter, more dependable nursery tech
The drug, intended for chronic weight management alongside diet and exercise, is now under the FDA’s new CNPV expedited review pathway
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
Globally, Abbott has received reports of 736 severe adverse events linked to the issue, including seven deaths (none in the US)
The State’s PPP model has already mobilised Rs. 150 crore in core infrastructure, while Thermo Fisher has invested Rs. 90 crore in the Bioprocess Design Centre and its co-located Customer Experience Centre
Subscribe To Our Newsletter & Stay Updated
